Sertindole, a new atypical antipsychotic for the treatment of schizophrenia

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 69-83

  Brown, Leigh Anne ^a   Levin, Gary M ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Capital District Psychiatric Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; CARBAMAZEPINE; CIMETIDINE; CLOZAPINE; DILTIAZEM; DISOPYRAMIDE; ENCAINIDE; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; KETOCONAZOLE; NEFAZODONE; NEUROLEPTIC AGENT; NIFEDIPINE; OLANZAPINE; PAROXETINE; PHENYTOIN; PLACEBO; PROKINETIC AGENT; PSYCHOTROPIC AGENT; QUINIDINE; RISPERIDONE; SERTINDOLE; UNINDEXED DRUG; VERAPAMIL;

BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; FEVER; HEADACHE; HUMAN; INSOMNIA; LONG QT SYNDROME; MULTICENTER STUDY; NEGATIVE SYNDROME; NOSE CONGESTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; INDOLES; SCHIZOPHRENIA;

EID: 0031975741     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994;330:681-90.
2. Miller DD. Schizophrenia: its etiology and impact. Pharmacotherapy 1996;16(1 part 2):2S-5.
3. American Psychiatric Association. Schizophrenia and other psychotic disorders. In: American Psychiatric Association diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Press, 1994:273-90.
4. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70-87.
5. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995;345:557-62.
6. Meltzer HY. Atypical antipsychotic drugs. In. Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1277-86.
7. Sandoz Pharmaceutical Corp. Clozaril (clozapine) package insert. East Hanover Park, NJ; 1995.
8. Lahti AC, Tamminga CA. Recent developments in the neuropharmacology of schizophrenia. Am J Health-Syst Pharm 1995;52(suppl 1):S5-8.
9. Leysen JE, Janssen PMF, Megens AAHP, Schotte A. Risperidone: a novel antipsychotic with balanced serotonindopamine antagonism, receptor occupancy profile, and pharmacologic profile. J Clin Psychiatry 1994;55(suppl 5):5-12.
10. Jackson DM, Evenden J, Mohell N. Preclinical findings with new antipsychotic agents: what makes them atypical. Acta Psychiatr Scand 1994;89(suppl 380):41-8.
11. Hyttel J, Arnt B, Costall A, et al. Pharmacological profile of the atypical neuroleptic sertindole. Clin Neuropharm 1992; 15(suppl 1 pt A):A267-8.
12. Risch SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy 1996;16(1 pt 2):11S-14.
13. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembol HL, Mier E. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991;22:239-50.
14. Jibson MD, Tandon R. A summary of research findings on the new antipsychotic drugs. Direction in Psychiatry 1996;16:i-viii.
15. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(suppl 11):12-25.
16. lshigooka J, Tsukahara T, Suzuki M, Fukuyama Y, Murasaki M, Miura S. The effect of sertindole in normal subjects: its safety, plasma concentrations, and effects on psychomotor functions. Neuropsychopharmacology 1994;10(suppl 3 part 2):139S.
17. Krystal J, D'Souza DC, Holgate KL, Staser JA, Silber CJ, Mack RJ. Sertindole: a multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life in stable schizophrenic patients. Poster presentation, 35th annual meeting of the American College of Neuropsycho-pharmacology, Puerto Rico, December 9-13, 1996.
18. van Kammen DP, McEvoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75.
19. McEvoy J, Borrison R, Small J, et al. The efficacy and tolerability of sertindole in schizophrenic patients: a pilot, double-blind, placebo-controlled, dose-ranging study (abstr]. Schizophr Res 1993;9:244.
20. Hale A, van der Burght M, Wehnert A, Sloth-Nielsen M. A European dose-range study comparing the efficacy, tolerability and safety of four doses of sertindole and one dose of haloperidol in schizophrenia patients. Poster presentation, 35th annual meeting of the American College of Neuropsycho-pharmacology, Puerto Rico, December 9-13, 1996.
21. Abbott Laboratories. Serlect (sertindole) investigator meeting phase III results. Abbott Park, IL: Author, 1996.
22. Daniel D, Targum S, Zimbroff D, et al. Efficacy, safety, and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Poster presentation, 34th annual meeting of the American College of Neuropsycho-pharmacology, Puerto Rico, December 11-15, 1995.
23. Tandon R, Silber C, Mack R. The action of sertindole on negative symptoms in schizophrenia. Poster presentation, 35th annual meeting of the American College of Neuropsycho-pharmacology, Puerto Rico, December 9-13, 1996.
24. Anonymous. New drugs for schizophrenia. FDC Rep 1996;58(30):5-7.
25. van Kammen D, Holgate KL, Sebree T, Zborowski J, Schmitz P, Wallin B. Two open-label, long-term safety studies of sertindole. Poster presentation, 34th annual meeting of the American College of Neuropsychopharmacology, Puerto Rico, December 9-13, 1996.
26. Swann A, Daniel D, Silber C, Mack R. Long term cardiovascular safety of sertindole. Poster presentation, 35th annual meeting of the American College of Neuropsycho-pharmacology, Puerto Rico, December 9-13, 1996.
27. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63.
28. Anonymous. Serlect and Seroquel included among first-line agents for acute schizophrenia in APA guideline. FDC Rep 1997;59(14):6-7.
29. Granneman GR, Wozniak P, Ereshefsky L, Silber C, Mack R. Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia. Poster presentation, 35th annual meeting of the American College of Neuropsycho-pharmacology, Puerto Rico, December 9-13, 1996.
30. Tan HL, Hou CJY, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 1995;122:701-14.
31. Nabulsi AA, Braus AJ, Mack RJ, et al. Reduction of hospital days in sertindole treated patients - one year findings. Poster presentation, annual meeting of the American Psychiatric Association, New York, May 4-9, 1996.
32. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment: a rationale and hypothesis. J Clin Psychiatry 1996;57(suppl 11):68-71.